Immunology

Latest News
June 24th 2025

Musculoskeletal Disorders in Postmenopausal Women Are Rising Worldwide

June 24th 2025

FDA Approves At-Home Belimumab Autoinjector for Pediatric Lupus Nephritis

June 12th 2025

Subcutaneous Tocilizumab Superior to Methotrexate in Chinese Patients With RA

February 21st 2025

AChR-Ab Titers Associated With Myasthenia Gravis Severity

February 13th 2025

Bimekizumab for Hidradenitis Suppurativa Offers Durable Disease Control in Long-Term Data

Video Interviews
View All
February 26th 2025

Real-World Data and Ongoing Research Into Bimekizumab-bkzx

February 24th 2025

Enhancing Patient Access Through Navigation Assistance

February 19th 2025

How Nipocalimab Targets Unmet Needs in Autoimmune Care

February 10th 2025

Bimekizumab-bkzx Expands Treatment Options for Inflammatory Conditions

October 29th 2024

Long-Term Bimekizumab Data Offer New Hope for HS Management

Podcasts
View All
October 29th 2024

Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa

More News

Myasthenia gravis | Image Credit: © Yurii Kibalnik-stock.adobe.com
February 7th 2025

Phase 3 Data Support Nipocalimab for Myasthenia Gravis

Maggie L. Shaw
The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and efficacy of nipocalimab for myasthenia gravis.
Jeff Stark, MD, UCB
February 6th 2025

Dr Jeff Stark: New Bimzelx Dose Offers Simplicity and Choice

Maggie L. Shaw Jeff Stark, MD
On October 14, 2024, the FDA approved a 320-mg single dose of bimekizumab-bkzx (Bimzelx; UCB) in a 2-mL prefilled syringe and autoinjector; both forms are now commercially available in the US.
Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine
January 29th 2025

How FcRn Blockade Targets Myasthenia Gravis Autoantibodies

Maggie L. Shaw Katie Abouzahr, MD
In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab works via FcRn blockade to reduce the circulating autoantibodies that drive myasthenia gravis.
Hidradenitis Suppurativa | Image Credit: © Yurii Kibalnik-stock.adobe.com
January 26th 2025

Hidradenitis Suppurativa, Porokeratosis Overlap in Rare Case Study

Emma Andrus
This case study explores a rare overlap of hidradenitis suppurativa and porokeratosis, as well as highlights the unique histopathology and complications
Christopher Sayed, MD
January 22nd 2025

Hidradenitis Suppurativa Onset and Treatment: Challenges and Hope for Patients

Maggie L. Shaw Christopher Sayed, MD
Christopher Sayed, MD, discusses how hidradenitis suppurativa typically presents and looks forward, following the November approval of bimekizumab.
Katie Abouzahr, MD, Johnson & Johnson
January 17th 2025

Understanding gMG: Autoantibodies and Life-Altering Muscle Weakness

Maggie L. Shaw
Generalized myasthenia gravis (gMG) is an autoantibody-driven chronic disease for which there is no cure.
Psoriatic arthritis | Image Credit: © Andrii-stock.adobe.com
January 15th 2025

Pain, Fatigue With Bimekizumab for PsA Tied to Swollen Joints

Maggie L. Shaw
Bimekizumab (Bimzelx; UCB Pharma) was approved by the FDA to treat psoriatic arthritis (PsA) on September 23, 2024, based on data from 2 phase 3 trials: BE OPTIMAL and BE COMPLETE.
hidradenitis suppurativa | Image Credit: © syahrir-stock.adobe.com
January 8th 2025

C-Reactive Protein May Guide HS Treatment Choices

Maggie L. Shaw
With high biologic treatment failure rates common among patients who have hidradenitis suppurativa (HS), investigators set out to evaluate the potential of biomarkers to estimate potential treatment response.
Chris Sayed, MD
January 3rd 2025

HS Treatment Goals: Better Quality of Life, Not Just Control

Maggie L. Shaw
For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurativa (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
SPD Highlights thumbnail
December 30th 2024

ICYMI: Highlights From SPD 2024

Maggie L. Shaw
The Society for Pediatric Dermatology (SPD) Annual Meeting took place in Toronto, Canada, July 11-15, with our top coverage including the hot topics of combating misinformation and improving care for children with dermatologic conditions.
AAD 2024 highlights thumbnail
December 22nd 2024

ICYMI: Highlights From AAD 2024

Maggie L. Shaw
The 2024 American Academy of Dermatology conference was held in San Diego, California March 8 to 11.
Top 5 Most-Read Immunology Articles of 2024
December 18th 2024

Top 5 Most-Read Immunology Articles of 2024

Maggie L. Shaw
Across 2024, top immunology news focused on ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis, highlighting studies on gut bacteria, radiographic progression, socioeconomic factors, and bimekizumab's persistent efficacy across multiple disease states.
Christopher Sayed, MD, UNC School of Medicine
December 12th 2024

Subcutaneous HS Therapy: Efficacy and Safety Insights

Maggie L. Shaw
In the continuation of our discussion with Chris Sayed, MD, University of North Carolina at Chapel Hill Department of Dermatology, he discusses the benefits of subcutaneous treatment of hidradenitis suppurativa, the chronic inflammatory skin condition.
Asembia Top 5 Thumbnail
December 3rd 2024

ICYMI: Highlights From Asembia 2024

Maggie L. Shaw
Presentations at the 2024 Asembia Specialty Pharmacy Summit focused on reshaping specialty pharmacy while keeping patients front and center.
Christopher Sayed, MD, UNC Chapel Hill
November 26th 2024

BE HEARD Trials Highlight Efficacy of Bimekizumab in Hidradenitis Suppurativa

Maggie L. Shaw
On November 20, the FDA approved bimekizumab (Bimzelx; UCB Pharma) for use in patients with moderate to severe hidradenitis suppurativa.
FDA | Image Credit: © Deni-stock.adobe.com
November 20th 2024

FDA Approves Bimekizumab in Hidradenitis Suppurativa

Maggie L. Shaw
This approval is the fifth overall for bimekizumab (Bimzelx; UCB Pharma) in the US, and they all have come in the last 13 months.
Psoriatic arthritis | Image Credit: © MQ-Illustrations-stock.adobe.com
November 19th 2024

New PsA Data Highlight Long-Term Benefits of Bimekizumab

Maggie L. Shaw
A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active psoriatic arthritis (PsA).
hidradenitis suppurativa | Image Credit: Yurii Kibalnik-stock.adobe.com
November 14th 2024

Underdiagnosis of Hidradenitis Suppurativa May Link to Socioeconomic Factors

Maggie L. Shaw
Investigators were seeking a greater understanding of risk factors for hidradenitis suppurativa, a chronic inflammatory skin disease, concentrating on how it presents in skin of color.
Hidradenitis suppurativa | Image Credit: © syahrir-stock.adobe.com
November 11th 2024

Possible Genetic Links Between Hidradenitis Suppurativa and CAD, Diabetes Risks

Maggie L. Shaw
In this study, investigators were seeking to uncover potential genetic correlations between hidradenitis suppurativa and downstream risk of cardiometabolic disease, such as coronary artery disease (CAD) and diabetes, in older adults.
Itchy pregnant belly | Image Credit: © chajamp stock.adobe.com
October 31st 2024

With Hidradenitis Suppurativa, Maternal and Offspring Outcomes May Suffer

Gayle Turim Dickstein
Novel evidence has emerged from a 16-year study that hidradenitis suppurativa can elevate risks of not only pregnancy and postpartum complications, but of morbidity—particularly metabolic- and immunology-related morbidity—for mother and child in the long term.
Bacteria in the gut | Image Credit: © Julien Tromeur-stock.adobe.com
October 25th 2024

Gut Bacteria Tied to Ankylosing Spondylitis Severity

Maggie L. Shaw
These authors investigated the potential influence of gut microbiota on ankylosing spondylitis pathophysiology.
Amit Garg, MD, Northwell Health
October 18th 2024

Bimekizumab Poised to Tackle Unmet HS Treatment Needs

Maggie L. Shaw
Hidradenitis suppurativa (HS) is an inflammatory, chronic disease with very high symptom and physical burdens, and it can get progressively worse over time if it's inadequately treated, explained Amit Garg, MD, founding chair, Department of Dermatology, Northwell Health.
psoriasis on a white man | Image credit: fusssergei - stock.adobe.com
October 14th 2024

Navigating Racial Disparities in Psoriatic Arthritis: Insights From Patient-Reported Outcomes

Skylar Jeremias
Individuals with self-reported moderate to severe psoriatic arthritis (PsA) face a higher disease burden, particularly among Black participants, highlighting the need for a better understanding of the interplay between PsA severity and racial and ethnic disparities.
Infertility concept | Image Credit: © andriano_cz-stock.adobe.com
October 4th 2024

Infertility Not Linked to Hidradenitis Suppurativa

Maggie L. Shaw
Previous research has linked hidradenitis suppurativa to infertility, but concrete data are lacking on causality of the chronic inflammatory skin condition in this setting.
FDA approved | Image credit: wladimir1804 - stock.adobe.com
September 23rd 2024

FDA Approves Bimekizumab for Psoriatic Arthritis, Nonradiographic AxSpA, Ankylosing Spondylitis

Rose McNulty
Bimekizumab-bkzx (Bimzelx) is now FDA approved for 4 chronic immune-mediated inflammatory diseases: psoriatic arthritis, nonradiographic axial spondyloarthritis (axSpA), ankylosing spondylitis, and moderate to severe plaque psoriasis.
Back pain due to axial spondyloarthritis | Image credit: Lila Patel - stock.adobe.com
September 23rd 2024

Patients With AxSpA Have Complex Needs, Require Tailored Treatment

Rose McNulty
New findings add to the understanding of the patient experience in axial spondyloarthritis (axSpA), which can help inform patient-centered clinical care.
FDA-ra2studio-stock.adobe.com.jpeg
September 18th 2024

FDA Approves Benralizumab for Eosinophilic Granulomatosis With Polyangiitis

Pearl Steinzor
The FDA approved benralizumab (Fasenra) for adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).
Image credit: Елена Бутусова - stock.adobe.com
September 13th 2024

Higher Risk of ILD in Patients With RA, PsA Initiating bDMARDs

Victoria Johnson
There were no differences in risk between patients with RA or PsA using or not using methotrexate.
The model’s predictions were in line with established cell distributions within each phenotype of rheumatoid arthritis. | Image credit: ArtemisDiana - stock.adobe.com
September 6th 2024

Machine Learning Effectively Characterizes Rheumatoid Arthritis Subtypes

Victoria Johnson
Investigators noted that a formal independent validation cohort needs to be developed to realize the full potential of the human model.
Bimekizumab showed sustained, consistent effectiveness to 52 weeks with or without methotrexate in psoriatic arthritis. | Image credit: stockdevil - stock.adobe.com
August 22nd 2024

Bimekizumab Shows Persistent Efficacy, Safety in Psoriatic Arthritis at 52 Weeks

Rose McNulty
Treatment with bimekizumab showed consistent efficacy through 52 weeks in patients with psoriatic arthritis in a post hoc analysis of the BE OPTIMAL, BE COMPLETE, and BE VITAL trials.
123>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo